Association of thiazolidinedione with a lower risk of Parkinson’s disease in a population with newly-diagnosed diabetes mellitus

Hsiu Li Lin, Hsiu Chen Lin, Yuan Fu Tseng, Jane Chen Jui Chao, Chien Yeh Hsu

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Objectives: We investigated the association of thiazolidinedione and its dose effect with the risk of Parkinson’s disease (PD) in patients with diabetes mellitus (DM). Methods: This study enrolled 38,521 patients with newly-diagnosed DM, between 2001 and 2013, and compared them to the matched subjects without DM. The hazard ratios (HRs) for PD were compared between the thiazolidinedione-treated and non-thiazolidinedione-treated groups of the study cohort, and between subgroups who received different cumulative dosages of thiazolidinedione. Results: We observed that 544 (1.4%) patients developed PD during the follow-up median duration of 6.2 years in patients with newly-diagnosed DM or had a higher risk for PD than patients without DM (HR = 1.150). In the study cohort, the risk of PD was significantly lower in the thiazolidinedione-treated group (HR = 0.399) compared to the non-thiazolidinedione-treated group. Thiazolidinedione reduced the risk of PD in a dose-dependent manner, with HRs ranging from 0.613 to 0.081 with defined daily doses of 0–90 to >720, respectively. Conclusions: Thiazolidinedione use was associated with a significantly reduced risk of PD in patients with newly-diagnosed DM. Further studies to elucidate the common mechanism of PD and DM may provide novel therapies for these two diseases.Key messages Newly-diagnosed diabetes mellitus slightly increases the risk for Parkinson’s disease. Thiazolidinedione is associated with a lower risk of Parkinson's disease in a dose-dependent manner in patients with newly-diagnosed diabetes mellitus.

Original languageEnglish
Pages (from-to)430-436
Number of pages7
JournalAnnals of Medicine
Volume50
Issue number5
DOIs
Publication statusPublished - Jul 4 2018

Fingerprint

Parkinson Disease
Diabetes Mellitus
Population
Cohort Studies
2,4-thiazolidinedione

Keywords

  • Diabetes mellitus
  • National Health Insurance Research Dataset
  • Parkinson’s disease
  • thiazolidinedione

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Association of thiazolidinedione with a lower risk of Parkinson’s disease in a population with newly-diagnosed diabetes mellitus. / Lin, Hsiu Li; Lin, Hsiu Chen; Tseng, Yuan Fu; Chao, Jane Chen Jui; Hsu, Chien Yeh.

In: Annals of Medicine, Vol. 50, No. 5, 04.07.2018, p. 430-436.

Research output: Contribution to journalArticle

@article{8cc61b885af84af7968f11261bc18eac,
title = "Association of thiazolidinedione with a lower risk of Parkinson’s disease in a population with newly-diagnosed diabetes mellitus",
abstract = "Objectives: We investigated the association of thiazolidinedione and its dose effect with the risk of Parkinson’s disease (PD) in patients with diabetes mellitus (DM). Methods: This study enrolled 38,521 patients with newly-diagnosed DM, between 2001 and 2013, and compared them to the matched subjects without DM. The hazard ratios (HRs) for PD were compared between the thiazolidinedione-treated and non-thiazolidinedione-treated groups of the study cohort, and between subgroups who received different cumulative dosages of thiazolidinedione. Results: We observed that 544 (1.4{\%}) patients developed PD during the follow-up median duration of 6.2 years in patients with newly-diagnosed DM or had a higher risk for PD than patients without DM (HR = 1.150). In the study cohort, the risk of PD was significantly lower in the thiazolidinedione-treated group (HR = 0.399) compared to the non-thiazolidinedione-treated group. Thiazolidinedione reduced the risk of PD in a dose-dependent manner, with HRs ranging from 0.613 to 0.081 with defined daily doses of 0–90 to >720, respectively. Conclusions: Thiazolidinedione use was associated with a significantly reduced risk of PD in patients with newly-diagnosed DM. Further studies to elucidate the common mechanism of PD and DM may provide novel therapies for these two diseases.Key messages Newly-diagnosed diabetes mellitus slightly increases the risk for Parkinson’s disease. Thiazolidinedione is associated with a lower risk of Parkinson's disease in a dose-dependent manner in patients with newly-diagnosed diabetes mellitus.",
keywords = "Diabetes mellitus, National Health Insurance Research Dataset, Parkinson’s disease, thiazolidinedione",
author = "Lin, {Hsiu Li} and Lin, {Hsiu Chen} and Tseng, {Yuan Fu} and Chao, {Jane Chen Jui} and Hsu, {Chien Yeh}",
year = "2018",
month = "7",
day = "4",
doi = "10.1080/07853890.2018.1488083",
language = "English",
volume = "50",
pages = "430--436",
journal = "Annals of Medicine",
issn = "0785-3890",
publisher = "Informa Healthcare",
number = "5",

}

TY - JOUR

T1 - Association of thiazolidinedione with a lower risk of Parkinson’s disease in a population with newly-diagnosed diabetes mellitus

AU - Lin, Hsiu Li

AU - Lin, Hsiu Chen

AU - Tseng, Yuan Fu

AU - Chao, Jane Chen Jui

AU - Hsu, Chien Yeh

PY - 2018/7/4

Y1 - 2018/7/4

N2 - Objectives: We investigated the association of thiazolidinedione and its dose effect with the risk of Parkinson’s disease (PD) in patients with diabetes mellitus (DM). Methods: This study enrolled 38,521 patients with newly-diagnosed DM, between 2001 and 2013, and compared them to the matched subjects without DM. The hazard ratios (HRs) for PD were compared between the thiazolidinedione-treated and non-thiazolidinedione-treated groups of the study cohort, and between subgroups who received different cumulative dosages of thiazolidinedione. Results: We observed that 544 (1.4%) patients developed PD during the follow-up median duration of 6.2 years in patients with newly-diagnosed DM or had a higher risk for PD than patients without DM (HR = 1.150). In the study cohort, the risk of PD was significantly lower in the thiazolidinedione-treated group (HR = 0.399) compared to the non-thiazolidinedione-treated group. Thiazolidinedione reduced the risk of PD in a dose-dependent manner, with HRs ranging from 0.613 to 0.081 with defined daily doses of 0–90 to >720, respectively. Conclusions: Thiazolidinedione use was associated with a significantly reduced risk of PD in patients with newly-diagnosed DM. Further studies to elucidate the common mechanism of PD and DM may provide novel therapies for these two diseases.Key messages Newly-diagnosed diabetes mellitus slightly increases the risk for Parkinson’s disease. Thiazolidinedione is associated with a lower risk of Parkinson's disease in a dose-dependent manner in patients with newly-diagnosed diabetes mellitus.

AB - Objectives: We investigated the association of thiazolidinedione and its dose effect with the risk of Parkinson’s disease (PD) in patients with diabetes mellitus (DM). Methods: This study enrolled 38,521 patients with newly-diagnosed DM, between 2001 and 2013, and compared them to the matched subjects without DM. The hazard ratios (HRs) for PD were compared between the thiazolidinedione-treated and non-thiazolidinedione-treated groups of the study cohort, and between subgroups who received different cumulative dosages of thiazolidinedione. Results: We observed that 544 (1.4%) patients developed PD during the follow-up median duration of 6.2 years in patients with newly-diagnosed DM or had a higher risk for PD than patients without DM (HR = 1.150). In the study cohort, the risk of PD was significantly lower in the thiazolidinedione-treated group (HR = 0.399) compared to the non-thiazolidinedione-treated group. Thiazolidinedione reduced the risk of PD in a dose-dependent manner, with HRs ranging from 0.613 to 0.081 with defined daily doses of 0–90 to >720, respectively. Conclusions: Thiazolidinedione use was associated with a significantly reduced risk of PD in patients with newly-diagnosed DM. Further studies to elucidate the common mechanism of PD and DM may provide novel therapies for these two diseases.Key messages Newly-diagnosed diabetes mellitus slightly increases the risk for Parkinson’s disease. Thiazolidinedione is associated with a lower risk of Parkinson's disease in a dose-dependent manner in patients with newly-diagnosed diabetes mellitus.

KW - Diabetes mellitus

KW - National Health Insurance Research Dataset

KW - Parkinson’s disease

KW - thiazolidinedione

UR - http://www.scopus.com/inward/record.url?scp=85050350090&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85050350090&partnerID=8YFLogxK

U2 - 10.1080/07853890.2018.1488083

DO - 10.1080/07853890.2018.1488083

M3 - Article

AN - SCOPUS:85050350090

VL - 50

SP - 430

EP - 436

JO - Annals of Medicine

JF - Annals of Medicine

SN - 0785-3890

IS - 5

ER -